2016 ASCO Annual Meeting - ASCO


Powered by SmugMug Log In
Michele Cavo, MD, presenting abstract 8000, Upfront autologous stem cell transplantation (ASCT) versus novel agent-based therapy for multiple myeloma (MM): A randomized phase 3 study of the European Myeloma Network (EMN02/HO95 MM trial) during Hematologic Malignancies?Plasma Cell Dyscrasia Oral Abstract Session

Michele Cavo, MD, presenting abstract 8000, Upfront autologous stem cell transplantation (ASCT) versus novel agent-based therapy for multiple myeloma (MM): A randomized phase 3 study of the European Myeloma Network (EMN02/HO95 MM trial) during Hematologic Malignancies?Plasma Cell Dyscrasia Oral Abstract Session

Chicago, IL - 2016 ASCO Annual Meeting - Michele Cavo, MD, presenting abstract 8000, Upfront autologous stem cell transplantation (ASCT) versus novel agent-based therapy for multiple myeloma (MM): A randomized phase 3 study of the European Myeloma Network (EMN02/HO95 MM trial) during Hematologic Malignancies?Plasma Cell Dyscrasia Oral Abstract Session at the American Society of Clinical Oncology (ASCO) Annual Meeting here today, Friday, June 3, 2016. Over 30,000 physicians, researchers, and healthcare professionals from over 100 countries are attending the 52nd Annual Meeting which is being held at the McCormick Place convention center. The Annual Meeting highlights the latest findings in all major areas of oncology from basic through clinical and epidemiological studies. Photo by © ASCO/Luke Franke 2016 Technical Questions: todd@medmeetingimages.com; ASCO Contact: corpcomm@asco.org